9 Einträge gefunden

1. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT

   1. Engler, Tobias
   2. Fasching, Peter A
   3. Lüftner, Diana
   4. Hartkopf, Andreas D
   5. Müller, Volkmar
   6. Kolberg, Hans-Christian
   7. Hadji, Peyman

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry

   1. Müller, Volkmar
   2. Hein, Alexander
   3. Hartkopf, Andreas D
   4. Fasching, Peter A
   5. Kolberg, Hans-Christian
   6. Hadji, Peyman
   7. Tesch, Hans

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"

   1. Schneeweiss, Andreas
   2. Ettl, Johannes
   3. Lüftner, Diana
   4. Beckmann, Matthias W
   5. Belleville, Erik
   6. Fasching, Peter A
   7. Fehm, Tanja N

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

   1. Hein, Alexander
   2. Hartkopf, Andreas D
   3. Emons, Julius
   4. Lux, Michael P
   5. Volz, Bernhard
   6. Taran, Florin-Andrei
   7. Overkamp, Friedrich

   2021 - Forschungsinformationssystem des UKE
5. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

   1. Michel, Laura L
   2. Hartkopf, Andreas D
   3. Fasching, Peter A
   4. Kolberg, Hans-Christian
   5. Hadji, Peyman
   6. Tesch, Hans
   7. Häberle, Lothar

   2020 - Forschungsinformationssystem des UKE
6. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

   1. Schneeweiss, Andreas
   2. Ettl, Johannes
   3. Lüftner, Diana
   4. Beckmann, Matthias W
   5. Belleville, Erik
   6. Fasching, Peter A
   7. Fehm, Tanja N

   2020 - Forschungsinformationssystem des UKE
7. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry

   1. Hartkopf, Andreas D
   2. Huober, Jens
   3. Volz, Bernhard
   4. Nabieva, Naiba
   5. Taran, Florin-Andrei
   6. Schwitulla, Judith
   7. Overkamp, Friedrich

   2018 - Forschungsinformationssystem des UKE
8. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry

   1. Müller, Volkmar
   2. Nabieva, Naiba
   3. Häberle, Lothar
   4. Taran, Florin-Andrei
   5. Hartkopf, Andreas D
   6. Volz, Bernhard
   7. Overkamp, Friedrich

   2018 - Forschungsinformationssystem des UKE
9. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

   1. Lux, Michael P
   2. Nabieva, Naiba
   3. Hartkopf, Andreas D
   4. Huober, Jens
   5. Volz, Bernhard
   6. Taran, Florin-Andrei
   7. Overkamp, Friedrich

   2018 - Forschungsinformationssystem des UKE - frei zugänglich